Home/Pipeline/HROW-324 (SHP-659)

HROW-324 (SHP-659)

Dry Eye Disease

Phase 2Active

Key Facts

Indication

Dry Eye Disease

Phase

Phase 2

Status

Active

Company

Harrow Health

About Harrow Health

Harrow Health is an integrated eyecare company with a mission to address unmet needs in ophthalmology through a diversified business model encompassing proprietary pharmaceuticals, non-sterile compounding, and sterile compounding. The company has achieved commercial success with several FDA-approved products and maintains a pipeline of development-stage candidates. Its strategic direction involves leveraging its ImprimisRx platform for distribution while advancing its proprietary pipeline through internal development and acquisitions.

View full company profile

Therapeutic Areas

Ophthalmology Anterior Segment Disease Ocular Surgery Dry Eye Disease Ocular Allergy Ocular Infection

Other Dry Eye Disease Drugs

Drug	Company	Phase	Status
CEQUA (cyclosporine)	Sun Pharmaceutical	Approved	Commercial
DE-120 (Ciclosporin ophthalmic gel)	Rohto Pharmaceutical	Phase 3	Active
DE-130 (Eicosapentaenoic Acid Ethyl Ester)	Santen Pharmaceutical	Phase 3	Active
DE-126 (SIP Receptor Modulator)	Santen Pharmaceutical	Phase 2	Active
DE-127	Santen Pharmaceutical	Phase 1	Active
OTX-CSI (cyclosporine insert)	Ocular Therapeutix	Phase 3	Completed (Did not meet primary endpoint)
voclosporin	Aurinia Pharmaceuticals	Phase 2/3	Discontinued (Nov 2023)
PL9643 (Melody-1)	Palatin Technologies	Phase 3	Active